# ASP Isotopes Inc.: overview ASPI · Nasdaq · CIK 1921865 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aspi.md) · [Financials](/companies/aspi/financials.md) · [Filings](/companies/aspi/filings.md) · [Insiders](/companies/aspi/insiders.md) Latest reported revenue: [$5.1m](/filings/0001193125-26-352603.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-352603). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.1](/filings/0001193125-25-288168.md) | [1.2 d](/filings/0001193125-26-151294.md) | [1.1](/filings/0001193125-26-232658.md) | [1.2](/filings/0001193125-26-352603.md) | [4.9](/filings/0001193125-25-288168.md) | [16.7 d](/filings/0001193125-26-151294.md) | [4.2](/filings/0001193125-26-232658.md) | [5.1](/filings/0001193125-26-352603.md) | | Gross margin | % | [27.0%](/filings/0001193125-25-288168.md) | [50.7% d](/filings/0001193125-26-151294.md) | [29.7%](/filings/0001193125-26-232658.md) | [47.7%](/filings/0001193125-26-352603.md) | [8.7%](/filings/0001193125-25-288168.md) | [12.5% d](/filings/0001193125-26-151294.md) | [39.9%](/filings/0001193125-26-232658.md) | [28.9%](/filings/0001193125-26-352603.md) | | Operating margin | % | [(499.6%)](/filings/0001193125-25-288168.md) | [(640.7%) d](/filings/0001193125-26-151294.md) | [(721.6%)](/filings/0001193125-26-232658.md) | [(999.1%)](/filings/0001193125-26-352603.md) | [(306.1%)](/filings/0001193125-25-288168.md) | [(150.2%) d](/filings/0001193125-26-151294.md) | [(595.4%)](/filings/0001193125-26-232658.md) | [(667.5%)](/filings/0001193125-26-352603.md) | | Net margin | % | [(676.2%)](/filings/0001193125-25-288168.md) | [(772.5%) d](/filings/0001193125-26-151294.md) | [(767.9%)](/filings/0001193125-26-352603.md) | [(6273.5%)](/filings/0001193125-26-352603.md) | [(263.7%)](/filings/0001193125-25-288168.md) | [(380.1%) d](/filings/0001193125-26-151294.md) | [(170.4%)](/filings/0001193125-26-232658.md) | [(663.5%)](/filings/0001193125-26-352603.md) | | Diluted EPS | $ per share | [(0.12)](/filings/0001193125-25-288168.md) | not reported | [(0.12)](/filings/0001193125-26-232658.md) | [(1.03)](/filings/0001193125-26-352603.md) | [(0.15)](/filings/0001193125-25-288168.md) | not reported | [(0.06)](/filings/0001193125-26-232658.md) | [(0.27)](/filings/0001193125-26-352603.md) | | Free cash flow | $m | [(9.3) d](/filings/0001193125-25-288168.md) | [(5.1) d](/filings/0001193125-26-151294.md) | [(5.5)](/filings/0001193125-26-232658.md) | [(9.7) d](/filings/0001193125-26-352603.md) | [(12.0) d](/filings/0001193125-25-288168.md) | [(20.2) d](/filings/0001193125-26-151294.md) | [(23.9)](/filings/0001193125-26-232658.md) | [(27.4) d](/filings/0001193125-26-352603.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001477932-24-001964.md) | [0.4](/filings/0000950170-25-047694.md) | [4.1](/filings/0001193125-26-151294.md) | [23.8](/filings/0001193125-26-151294.md) | | Gross margin | % | not reported | [32.1%](/filings/0000950170-25-047694.md) | [38.6%](/filings/0001193125-26-151294.md) | [14.3%](/filings/0001193125-26-151294.md) | | Operating margin | % | not reported | [(3704.6%)](/filings/0000950170-25-047694.md) | [(636.0%)](/filings/0001193125-26-151294.md) | [(251.2%)](/filings/0001193125-26-151294.md) | | Net margin | % | not reported | [(3762.9%)](/filings/0000950170-25-047694.md) | [(782.4%)](/filings/0001193125-26-151294.md) | [(670.2%)](/filings/0001193125-26-151294.md) | | Diluted EPS | $ per share | not reported | [(0.49)](/filings/0000950170-25-047694.md) | [(0.63)](/filings/0001193125-26-151294.md) | [(2.11)](/filings/0001193125-26-151294.md) | | Free cash flow | $m | [(7.4)](/filings/0001477932-24-001964.md) | [(7.7)](/filings/0000950170-25-047694.md) | [(26.4)](/filings/0001193125-26-151294.md) | [(47.4)](/filings/0001193125-26-151294.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aspi/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $57.3m | 9,217,198 | | Added +889,054 | | [Encompass Capital Advisors LLC](/funds/1541901.md) | 2026-06-30 | $40.8m | 6,561,754 | | Reduced −350,300 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $31.0m | 4,982,953 | | Reduced −77,511 | | [Rovida Investment Management Ltd](/funds/2053064.md) | 2026-06-30 | $25.5m | 4,100,000 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $20.2m | 3,247,633 | | Added +405,924 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $18.3m | 2,945,901 | | Added +205,437 | | [Alyeska Investment Group, L.P.](/funds/1453072.md) | 2026-06-30 | $17.7m | 2,843,503 | | Added +151,337 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $16.3m | 2,612,700 | Call | Reduced −372,600 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $16.1m | 2,595,573 | | Added +273,414 | | [EXCHANGE TRADED CONCEPTS, LLC](/funds/1457320.md) | 2026-06-30 | $14.0m | 2,255,509 | | Added +71,955 | ## Recent filings [All 388 filings](/companies/aspi/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:15 ET | [8-K](/filings/0001193125-26-431084.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-431084 | | 2026-10-15 | 08:22 ET | [8-K](/filings/0001193125-26-422325.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-422325 | | 2026-10-02 | 06:01 ET | [8-K](/filings/0001477932-26-005971.md) | 7.01 Regulation FD disclosure | 0001477932-26-005971 | | 2026-09-08 | 09:20 ET | [8-K](/filings/0001193125-26-384527.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-384527 | | 2026-08-20 | 17:17 ET | [8-K](/filings/0001477932-26-005196.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001477932-26-005196 | | 2026-08-20 | 08:05 ET | [8-K](/filings/0001193125-26-358072.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-358072 | | 2026-08-18 | 08:05 ET | [8-K](/filings/0001193125-26-354745.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-354745 | | 2026-08-14 | 17:14 ET | [10-Q](/filings/0001193125-26-352603.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352603 | | 2026-08-06 | 08:12 ET | [8-K](/filings/0001193125-26-336859.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-336859 | | 2026-08-05 | 08:05 ET | [8-K](/filings/0001193125-26-333911.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-333911 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-151294.md), filed Apr 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/0e706e49-f928-428d-bb26-21bada6b1cea) ## About the filer - CIK: 1921865 - Tickers: ASPI - Exchange: Nasdaq - SIC code: 2890 Miscellaneous Chemical Products - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 16:17 ET. No prices; not investment advice.